01 /
Targeted immunity
Built to support stronger and more directed immune activation across relevant disease settings.
Immunology. Innovation. Translation.
Precision at the
heart of immunity.
Developing vaccine and immunotherapy approaches through targeted immune activation, modular design and translational research.
Oslo, Norway
The NextGenVax perspective
A more deliberate way
to activate immunity.
Immune responses are complex.
Our approach starts with precision.
NextGenVax brings antigen design, immune-enhancing functionality and targeting concepts into a modular technology framework. We are exploring how these elements can support vaccine and immunotherapy development across infectious diseases and cancer.
Our focus is on connecting scientific innovation with the experiments, collaborations and development decisions needed for translation.
Research-led. Translation-minded.
Our platform
Three elements.
One adaptable approach.
A modular framework for investigating targeted immune activation, with mucosal vaccine delivery as a development focus.
01Antigen design
Selecting disease-relevant antigens and exploring modular designs that can be adapted to different research applications.
02Immune enhancement
Investigating immune-enhancing functionality to understand how platform design influences the quality and direction of immune responses.
03Targeted delivery
Exploring targeting and delivery concepts, including mucosal approaches, while keeping manufacturability and translational evaluation in view.
Research focus
A platform.
Multiple possibilities.
APPLICATION / 01Concept illustration · mucosal immunity
Infectious diseases
Exploring immunity
where exposure begins.
Mucosal vaccine concepts offer a route to investigate immune responses at the sites where many pathogens first encounter the body. Our research approach connects antigen strategy, delivery and immune characterization.
Discuss a research collaborationAPPLICATION / 02Concept illustration · immune interaction
Cancer immunotherapy
Bringing targeted immune
activation into oncology.
We are exploring the application of modular immune-enhancing and targeting concepts to cancer research. Translational assays help connect platform design with disease-relevant questions and guide the next development decisions.
Discuss an oncology collaborationInnovation support
Translational growth
support.
NextGenVax is advancing a differentiated vaccine platform designed to address important limitations of conventional approaches.
Our innovation strategy focuses on scalable mucosal vaccine solutions that can be adapted across infectious disease and cancer applications, supporting faster development and broader future accessibility.
By building with translation in mind from the beginning, we strengthen readiness for preclinical validation, clinical development, and future partnering opportunities.
Leadership
Expert scientific
leadership.
Our advisory and leadership network brings together expertise across immunology, oncology, translational medicine, and biotechnology development.
This scientific depth supports our ability to connect complex molecular innovation with practical development pathways, helping ensure that promising technologies move toward meaningful patient impact.
Operational hub
Oslo life science
cluster.
Located in the heart of Oslo’s life science environment, our operational base supports collaboration, research development, and international innovation engagement.
02 /
Modular design
Flexible technology architecture adaptable across multiple infectious disease and oncology applications.
03 /
Translational focus
Designed with preclinical validation, clinical readiness, and scale-up potential in mind.
04 /
Global relevance
Created to support broader accessibility and future impact across diverse healthcare settings.
Contact
Get in
touch.
Interested in partnering, licensing, investing, or scientific collaboration? Send us a message and we will get back to you.
Oslo, NorwayUniversitetsgata 2, 0164 Oslo